Fernando Avila, MD
Pain Medicine · San Antonio, TXNPI 1538158050
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.8%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Saluda Medical Americas, Inc. at 29.6% of the total.
Across 298 payments — averaging $28.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$3K
- Curonix LLC$965
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$840
- IBSA Pharma Inc.$750
- Pfizer$702
- AbbVie$449
- plus $2K from 27 others
What the payments were for
- Consulting fees$7509%
- Travel & lodging$2,86433%
- Food & beverage$4,89057%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 8 | $2,545 |
| Curonix LLC | 8 | $965 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 58 | $840 |
| IBSA Pharma Inc. | 1 | $750 |
| Pfizer | 53 | $702 |
| AbbVie(2 entities) | 34 | $449 |
| Collegium Pharmaceutical, Inc. | 21 | $262 |
| Boston Scientific | 11 | $240 |
| Amgen | 15 | $225 |
| Teva Pharmaceuticals USA, Inc. | 8 | $199 |
| Si-bone, Inc. | 3 | $199 |
| Supernus Pharmaceuticals, Inc. | 16 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $143 |
| Medtronic | 4 | $129 |
| Merck | 6 | $120 |
| Eisai Inc. | 4 | $90 |
| Scilex Pharmaceuticals Inc. | 6 | $86 |
| Redhill Biopharma Inc. | 4 | $68 |
| Daiichi Sankyo Inc. | 4 | $64 |
| Novartis | 3 | $53 |
| Abbott | 2 | $39 |
| MDD US Operations, LLC | 2 | $34 |
| Nevro Corp. | 2 | $30 |
| Organogenesis Inc. | 1 | $28 |
| Radius Health, Inc. | 2 | $26 |
| Shionogi Inc | 2 | $26 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| AstraZeneca | 1 | $18 |
| West Therapeutics Development, LLC | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Antares Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,606 in reported general payments places this provider in the 70th percentile of 583 pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 22 | $460 |
| Duloxetine Hcl | 35 | $438 |
| Tizanidine Hcl | 26 | $260 |
| Cyclobenzaprine Hcl | 23 | $140 |
| Meloxicam | 28 | $76 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in San Antonio
- Ellen LinSan Antonio$118K
- Prabhdeep GrewalSan Antonio$48K
- Roberto DiazSan Antonio$37K
- Ricardo AlvaradoSan Antonio$23K
- Charles BryantSan Antonio$23K
- Melissa MurphyGrapevine$653K
- Shiraz YazdaniLubbock$514K
- Aaron CalodneyTyler$296K
- Candice BurnetteSugar Land$265K
- Ashley Bailey-ClassenFort Worth$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.